Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.

Novo Nordisk is pushing the FDA to block compounders from making copies of its Ozempic and Wegovy, saying the weight-loss treatments are too complex to safely replicate. Why it matters: It's the latest twist in the battle between pharma giants and compounders over the law that allows copies of patent-protected drugs amid shortages.

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,

FDA recalls thousands of antidepressant bottles due to cancer-causing chemical{beacon} Health Care Health Care   The Big Story Novo